卡瑞利珠-话题@MedSci

#卡瑞利珠#

27篇内容 | 1071人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1502863, encodeId=fac1150286309, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, objectTitle=Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）, objectType=article, longId=194143, objectId=2d2a194143a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d2a194143a2, replyNumber=0, likeNumber=35, createdTime=2020-05-15, rootId=0, userName=by2012, userId=8d779566916, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d2a194143a2, moduleTitle=Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d2a194143a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1502862, encodeId=f69b150286278, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, objectTitle=AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究, objectType=article, longId=193104, objectId=5d7319310411, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d7319310411, replyNumber=0, likeNumber=34, createdTime=2020-04-30, rootId=0, userName=by2012, userId=8d779566916, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d7319310411, moduleTitle=AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d7319310411)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1502861, encodeId=5d991502861e2, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, objectTitle=从临床药理特性，看卡瑞利珠单抗的独特优势, objectType=article, longId=178882, objectId=e5441e8882e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5441e8882e3, replyNumber=0, likeNumber=62, createdTime=2019-09-06, rootId=0, userName=by2012, userId=8d779566916, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5441e8882e3, moduleTitle=从临床药理特性，看卡瑞利珠单抗的独特优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5441e8882e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1502860, encodeId=5a831502860cc, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, objectTitle=卡瑞利珠单抗有望开启食管鳞癌免疫治疗新征程, objectType=article, longId=175266, objectId=e6f71e52669d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6f71e52669d, replyNumber=0, likeNumber=44, createdTime=2019-07-13, rootId=0, userName=by2012, userId=8d779566916, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6f71e52669d, moduleTitle=卡瑞利珠单抗有望开启食管鳞癌免疫治疗新征程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6f71e52669d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1502859, encodeId=c14e1502859b4, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, objectTitle=J Clin Oncol：突破，完全缓解率71%！卡瑞利珠单抗联合治疗复发难治霍奇金淋巴瘤新进展, objectType=article, longId=168859, objectId=79c5168859a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79c5168859a5, replyNumber=0, likeNumber=36, createdTime=2019-06-22, rootId=0, userName=by2012, userId=8d779566916, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79c5168859a5, moduleTitle=J Clin Oncol：突破，完全缓解率71%！卡瑞利珠单抗联合治疗复发难治霍奇金淋巴瘤新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79c5168859a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1502858, encodeId=3b7d1502858db, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, objectTitle=卡瑞利珠单抗联合GEMOX一线治疗胆道癌单臂探索性研究亮相ASCO舞台, objectType=article, longId=168240, objectId=c62b16824082, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62b16824082, replyNumber=0, likeNumber=34, createdTime=2019-06-14, rootId=0, userName=by2012, userId=8d779566916, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62b16824082, moduleTitle=卡瑞利珠单抗联合GEMOX一线治疗胆道癌单臂探索性研究亮相ASCO舞台, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62b16824082)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1502857, encodeId=96c1150285ef8, content=<a href='/topic/show?id=d56636526e4' target=_blank style='color:#2F92EE;'>#卡瑞利珠#</a>, objectTitle=阿帕替尼+卡瑞利珠单抗联合出击，为NSCLC患者带来新希望, objectType=article, longId=168141, objectId=9b1716814124, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b1716814124, replyNumber=0, likeNumber=43, createdTime=2019-06-13, rootId=0, userName=by2012, userId=8d779566916, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b1716814124, moduleTitle=阿帕替尼+卡瑞利珠单抗联合出击，为NSCLC患者带来新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b1716814124)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

卡瑞利珠

2020-05-29

by2012 (审核中...)

前往app查看评论内容

#卡瑞利珠#

Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）

2020-05-15

by2012 (审核中...)

前往app查看评论内容

#卡瑞利珠#

AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究

2020-04-30

by2012 (审核中...)

前往app查看评论内容

#卡瑞利珠#

从临床药理特性，看卡瑞利珠单抗的独特优势

2019-09-06

by2012 (审核中...)

前往app查看评论内容

#卡瑞利珠#

卡瑞利珠单抗有望开启食管鳞癌免疫治疗新征程

2019-07-13

by2012 (审核中...)

前往app查看评论内容

#卡瑞利珠#

J Clin Oncol：突破，完全缓解率71%！卡瑞利珠单抗联合治疗复发难治霍奇金淋巴瘤新进展

2019-06-22

by2012 (审核中...)

前往app查看评论内容

#卡瑞利珠#

卡瑞利珠单抗联合GEMOX一线治疗胆道癌单臂探索性研究亮相ASCO舞台

2019-06-14

by2012 (审核中...)

前往app查看评论内容

#卡瑞利珠#

阿帕替尼+卡瑞利珠单抗联合出击，为NSCLC患者带来新希望

2019-06-13

科室
- - 订阅+
  - 更多科室
工具
服务